rezvilutamide
Sponsor AZN · listed as AZN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2027-03-31
As disclosedMar 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT07241416
PhasePHASE3
StatusRECRUITING
Lead sponsorJiangsu HengRui Medicine Co., Ltd.
Listed asAZN
Condition(s)Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More AZN catalysts